BioSpace News Archive

New research program between BioNTech and the University of Pennsylvania

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that Andrew Wright has been appointed as Financial Controller & Company Secretary, a non-Board position, and that Lawrence Pemble, Chief Operating Officer, will step down from the Board, both with immediate effect.

Interventions that promote healthy microbiome acquisition in infants key to curbing chronic childhood diseases

Phase 1 data show favourable safety profile

Oxurion NV announced today that it entered into a strategic research collaboration with Beta Therapeutics Pty Ltd

Boehringer Ingelheim and Epizyme signed a global collaboration deal to identify, develop and market cancer therapies. The deal could exceed $300 million.

United Therapeutics bets a significant amount of money on the potential commercialization of ralinepag.

Cristal Therapeutics has appointed Dr. Axel Mescheder to the role of Chief Executive Officer (CEO) with immediate effect. He will also serve as Chief Medical Officer (CMO).

Proceeds to enable advancement of lead product candidate INT230-6 into Phase 2 clinical development for solid tumors

A*STAR scientists successfully grow skin on a credit-card sized device that facilitates testing of pharmaceuticals, cosmetics, and other chemicals; Awarded the Global 3Rs Award for reducing animal use in scientific research